Workflow
科恩-斯蒂尔斯(CNS)
icon
搜索文档
Cohen & Steers Infrastructure Fund, Inc. Declares Distributions for January, February, and March 2026
Prnewswire· 2025-12-18 05:00
NEW YORK, Dec. 17, 2025 /PRNewswire/ -- The Board of Directors of the Cohen & Steers Infrastructure Fund, Inc. (the "Fund") announced today the monthly distributions for January, February, and March 2026 as summarized in the charts below: Ticker Fund Name Monthly Dividend UTF Cohen & Steers Infrastructure Fund, Inc. $0.155 The distributions will be made on the following schedule: Month      Ex-Dividend/ Record Date      Payable Date January Jan. 13, 2026 Jan. 30, 2026 February Feb. ...
CNS Pharmaceuticals Announces CEO Transition
Accessnewswire· 2025-12-17 20:00
Industry veteran Rami Levin, MBA appointed as President & Chief Executive Officer HOUSTON, TX / ACCESS Newswire / December 17, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced John Climaco has stepped down as Chief Executive Officer of CNS Pharmaceuticals and Rami Levin, MBA, has been appointed as President & Chief ...
Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Declares Year-End Capital Gain Distribution - Cohen & Steers (NYSE:CNS), COHEN & STEERS QUALITY (NYSE:RQI)
Benzinga· 2025-12-17 06:36
NEW YORK, Dec. 16, 2025 /PRNewswire/ -- The Board of Directors of the Cohen & Steers Quality Income Realty Fund, Inc. (NYSE: RQI) (the "Fund") has declared a year-end capital gain distribution, as summarized in the chart below. In addition to the regular monthly distribution, this year-end capital gain distribution is being paid to allow the Fund to meet its 2025 distribution requirement for federal excise tax purposes. A substantial portion of the total distribution will be taxable to shareholders in 2025. ...
Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Declares Year-End Capital Gain Distribution
Prnewswire· 2025-12-17 06:36
NEW YORK, Dec. 16, 2025 /PRNewswire/ -- The Board of Directors of the Cohen & Steers Quality Income Realty Fund, Inc. (NYSE: RQI) (the "Fund") has declared a year-end capital gain distribution, as summarized in the chart below. In addition to the regular monthly distribution, this year-end capital gain distribution is being paid to allow the Fund to meet its 2025 distribution requirement for federal excise tax purposes. A substantial portion of the total distribution will be taxable to shareholders in 2025 ...
Cohen & Steers Closed-End Funds Declare Distributions for January, February and March 2026
Prnewswire· 2025-12-17 06:34
NEW YORK, Dec. 16, 2025 /PRNewswire/ -- The Board of Directors of the Cohen & Steers Closed-End Funds announced today the monthly distributions for January, February and March 2026, as summarized in the charts below: Ticker Fund Name Monthly Dividend FOF Cohen & Steers Closed-End Opportunity Fund, Inc. $0.087 LDP Cohen & Steers Limited Duration Preferred and Income Fund, Inc. $0.131 PSF Cohen & Steers Select Preferred and Income Fund, Inc. $0.126 PTA Cohen & Steers Tax-Advantaged Preferred Se ...
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies
Globenewswire· 2025-12-16 20:00
SAN FRANCISCO and BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- SandboxAQ and MapLight Therapeutics, Inc. (Nasdaq: MPLT) announced today that the companies have entered into a strategic collaboration to discover and develop potential first-in-class therapies targeting a novel G protein-coupled receptor (GPCR) for the treatment of central nervous system (CNS) disorders. Under the terms of the agreement, SandboxAQ received an upfront payment and will be eligible to receive additional preclinical, development, reg ...
Cohen & Steers Launches Infrastructure Opportunities and Short Duration Preferred Securities Active ETFs
Prnewswire· 2025-12-10 22:43
NEW YORK, Dec. 10, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) is adding to its suite of actively managed exchange-traded funds (ETFs) with the launch of two new strategies: the Cohen & Steers Infrastructure Opportunities Active ETF (NYSE Arca: CSIO) and the Cohen & Steers Short Duration Preferred and Income Active ETF (NYSE Arca: CSSD). CSIO and CSSD began trading on the NYSE Arca today. Daniel Noonan, Head of Global Distribution, said:  "Active ETFs are the fastest growing investment vehicle in ...
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for November 2025
Prnewswire· 2025-12-09 05:24
NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $91.9 billion as of November 30, 2025, an increase of $1.3 billion from assets under management of $90.6 billion at October 31, 2025. The increase was due to market appreciation of $2.0 billion, partially offset by net outflows of $502 million and distributions of $151 million. Assets Under Management(unaudited) ($ in millions) AUM   Net Market  AUM By investment vehicle: ...
Cohen & Steers Named a "Best Place to Work in Money Management" by Pensions & Investments for Sixth Consecutive Year
Prnewswire· 2025-12-08 21:30
thNEW YORK, Dec. 8, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today that it has been named as one of the "Best Places to Work in Money Management" for the sixth consecutive year by Pensions & Investments, a global news source of money management. P&I's 14 annual recognition program is dedicated to identifying and recognizing the best employers in the money management industry. Joseph Harvey, Chief Executive Officer of Cohen & Steers, said:"We are honored to receive the 'Best Place to ...
CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Accessnewswire· 2025-11-17 21:35
公司财务状况与运营展望 - 公司现金预计足以支持运营至2026年下半年 [1] - 公司报告了截至2025年9月30日的2025年第三季度财务业绩 [1] 公司战略与研发重点 - 公司专注于推进源自成熟药物类别的下一代抗癌疗法 [1] - 核心研发策略是将这些疗法设计为能够穿越血脑屏障 从而可能提高对患者的疗效 [1] 核心研发项目进展 - 主导项目TPI 287正朝着针对多形性胶质母细胞瘤(GBM)的2期研究推进 [1] - GBM是最具侵袭性的脑癌类型之一 确诊后的中位生存期仅为15个月左右 [1] - 公司致力于为抗击脑癌和中枢神经系统癌症的患者提供有意义的研发进展 [1]